

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**石四藥集團有限公司**  
**SSY Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

**VOLUNTARY ANNOUNCEMENT**  
**UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug clinical trial for Pitavastatin Calcium Tablets (2mg and 1mg), Tenofovir Disoproxil Fumarate Tablets (300mg) and Entecavir Capsules (1mg and 0.5mg) from the China Food and Drug Administration.

Pitavastatin Calcium Tablets are mainly used for treatment of hypercholesterolemia. Tenofovir Disoproxil Fumarate is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Entecavir is mainly used for treatment of hepatitis B.

The abovementioned three drugs are new drugs under previous type 6 chemical drug.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Company Secretary*

Hong Kong, 27 October 2016

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*